A Phase 2 interventional study of AGuIX® and Whole Brain Radiation Therapy in Brain Metastases, Adult and Radiotherapy, sponsored by University Hospital, Grenoble. Completed at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by University Hospital, Grenoble · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Brain Neoplasms with a site in France — 38 open to participants now, 52 under way, 6 of them phase 3. Brain Neoplasms · France.
Among the 172 studies in Brain Neoplasms with a site in France, this one is the 50th largest by enrollment of the 132 interventional ones that give a count, is one of 11 that started in 2019, is one of 40 in phase 2, and was the 97th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →38 of the 172 studies in Brain Neoplasms with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Belgium and 10 more countries
Ages 18+
Center Eugene Marquis · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Beta Emitting Accurate Monitored Systems · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 56 · Phase 3 25
First in 1996; this study’s year is marked. 11 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 70 across the 132 interventional studies, 100 across the 37 observational. Of the 102 that completed or were terminated, 21 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 172 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 4 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Brain Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT07558395Institut National de la Santé Et de la Recherche Médicale, FranceEffectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour | 2026-12 |
| NCT06413706Eli Lilly and CompanyA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | 2027-02 |
| NCT07274397Beta Emitting Accurate Monitored SystemsAssessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma | 2027-04-17 |
| NCT06962215University Hospital, BrestThe Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery (IPSIMANON) | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 172 studies in Brain Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Prospective Randomized Open Blinded Endpoint phase II clinical trial. The study will be adaptive: an interim analysis is planned after enrolment of 20 patients in each arm of treatment (WBRT and AGuIX® + WBRT), to select and continue the study with group(s) that present the best response rate to the experimental treatment (AGuIX® + WBRT).
The main endpoint will be evaluated by a blinded endpoint committee.
The occurrence of brain metastases is a common event in the history of cancer and negatively affects the life expectancy of patients. Their incidence varies between 15 and 50% according to the histologic types. Surgery, stereotactic radiosurgery, radiotherapy and chemotherapy are the main treatments currently proposed.
For patients with multiple brain metastases, whole brain radiation therapy (WBRT) remains the standard of care. However, the median overall survival is less than 6 months and new approaches need to be developed to improve treatment of these patients.
In this context, the weak control of the disease comes from three main factors: the multiplicity of the brain lesions, the radioresistance of certain histologies and the poor distribution of cytotoxic agents in brain metastases.
The use of radiosensitizing agents is here of great interest. The radiosensitizing agent chosen in this study is AGuIX®. It is a Gadolinium-chelated polysiloxane based nanoparticle developed by NH TherAguix company for its theranostic properties (radiosensitization and diagnosis by multimodal imaging). Preclinical studies have demonstrated the radiosensitizing effect of AGuIX® in vivo in 8 tumor models xenografted in rodents, and particularly in brain tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Extracranial disease:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Drug: AGuIX® + WBRT Other Names: Gadolinium-chelated polysiloxane based nanoparticles 3 intravenous injections at 100mg/kg * D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT) * Fr1: AGuIX® injection before the first radiation session * Fr6: AGuIX® injection before the sixth radiation session 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
Drug: AGuIX® · Radiation: Whole Brain Radiation Therapy
Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
Radiation: Whole Brain Radiation Therapy
3 intravenous injection at 100mg/kg * D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT) * Fr1: AGuIX® injection before the first radiation session * Fr6: AGuIX® injection before the sixth radiation session
Also known as: Gadolinium-chelated polysiloxane based nanoparticles
30 Gy in 10 fractions of 3 Gy over 2-3 weeks
Also known as: WBRT
Best objective intracranial response rate - intent-to-treat
Evaluation of brain metastases response, according to RECIST v1.1 criteria (or modified RECIST) by MRI, with MRI centralized reading
Time frame: at 6 weeks
Best objective intracranial response rate - intent-to-treat
Evaluation of brain metastases response, according to RECIST v1.1 criteria (or modified RECIST) by MRI, with MRI centralized reading
Time frame: at 3 months
Evaluation of the quality of life
Quality of life test score EORTC QLQ C30
Time frame: at D0, 6 weeks, 3, 6, 9, 12 months
Evaluation of the quality of life
Quality of life test score EORTC QLQ BN20
Time frame: at day 0, 6 weeks, 3, 6, 9, 12 months
Neurocognitive evaluation
Neurocognitive test (MoCA)
Time frame: at Day 0, 6 weeks, 3, 6, 9, 12 months
Best objective intracranial response rate - per-protocol
Evaluation of brain metastases response on per-protocol population, according to RECIST v1.1 criteria (or modified RECIST), by MRI with centralized reading
Time frame: at 6 weeks and 3 months
Evaluation of the intracranial response rate
Evaluation of brain metastases response, according to RANO, to RECIST v1.1 criteria, and as the evolution of the sum of longest diameters (for all metastases with a sum of diameters \> 1cm), by MRI, at 6 weeks and 3, 6, 9 and 12 months
Time frame: for 12 months
Evaluation of individual metastasis response
Evaluation of individual brain metastasis response, for all metastases with the sum of diameters \> 1cm, by MRI rate
Time frame: at 6 weeks and 3, 6, 9 and 12 months
Intracranial progression-free survival
Evaluation of the time between the start of the treatment and the occurence of intracranial progression or neuriologic death
Time frame: at 12 months
Intracranial progression-free survival, brain survival
Death related to brain metastases progression
Time frame: at 12 months
Overall survival
Death
Time frame: at 12 months
Change in steroid dependence
Reporting of daily steroid dose
Time frame: at 6 weeks and 3, 6, 9 and 12 months
Incidence of adverse events
Reporting of adverse events by type, frequency and severity for both treatments (WBRT and AGuIX® + WBRT)
Time frame: at 6 weeks and 3, 6, 9 and 12 months
MRI study of the distribution of the product in brain metastases
MRI evaluation of contrast enhancement at D0 after AGuIX® injection
Time frame: Day 0
Plan to share: Yes — The provision of patient-level individualized databases (= pseudonymized data) may only be carried out within an appropriate regulatory and contractual framework to ensure compliance with applicable regulations (including the GDPR). Consequently, the data cannot be made freely available; however, you may contact the sponsor (CHUGA) with any requests for access to the data using the following addresses: juristerecherche@chu-grenoble.fr, ArcPromoteur@chu-grenoble.fr, AccueilRecherche@chu-grenoble.fr . This allows to review requests to determine how to respond to them in full compliance with the law, particularly in accordance with regulations regarding the protection of personal data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Availability date: from the moment that the regulatory and contractual framework has been approved by CHUGA. End date: Subject to applicable regulations, the data will be made available for as long as necessary to achieve the scientific objectives.
Access criteria: Anyone who would like to access to study data and/or study documents should be submitted the request to the sponsor via juristerecherche@chu-grenoble.fr, ArcPromoteur@chu-grenoble.fr and/or AccueilRecherche@chu-grenoble.fr. Any data sharing will be subject to the implementation of an appropriate legal and contractual framework, including, where applicable, the execution of a data access agreement, and must fully comply with French regulations on personal data protection (including the French Data Protection Act and applicable CNIL reference methodologies, MR001 for the present clinical trial), the EU General Data Protection Regulation, and the terms of the informed consent provided by participants.
Data sharing details ↗ · www.chu-grenoble.fr
Ran from Mar 2019 to primary completion in Sep 2024, 66 months.
Of 208 non-industry phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 100. This study's 66 months is close to that.
Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AGuIX
University Hospital, Grenoble →